ClinicalTrials.gg

Program

naperiglipron

Also written as “LY3549492” and “[14C]-LY3549492”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Body Weight, led by Eli Lilly.

Furthest: phase 2, since Nov 6, 202310 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly101 open or runningphase 2since Nov 6, 2023Feb 16, 2021Sep 2027phase 2 · NCT06143956
  • Named in Eli Lilly’s own pipeline as Naperiglipron, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 16, 2021First study: phase 1 study in HealthyFirst studyNCT04758234 · 54 enrolled · United States
  2. Apr 8, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05327595 · 80 enrolled · Germany
  3. Nov 6, 2023Phase 2 study in ObesityNCT06143956 · 1,481 planned · United States, Argentina
  4. Dec 20, 2023Phase 1 study in Healthy MaleNCT06194500 · 18 enrolled · United Kingdom
  5. Nov 8, 2024Phase 2 study in ObesityNCT06683508 · 288 enrolled · United States
  6. Mar 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06869018 · 92 enrolled · Japan
  7. Jun 13, 2025Phase 2 study in ObesityNCT07030868 · 1 enrolled · United States, Argentina
  8. Jul 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07073170 · 36 enrolled · China
  9. Jul 18, 2025Phase 2 study in Body WeightNCT07085468 · 1 enrolled · United States, Canada
  10. Nov 14, 2025Phase 1 study in ObesityNCT07232732 · 120 enrolled · United States

Ahead

  1. Sep 2027Primary completion: phase 2 study in ObesityNCT06143956

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07232732Obesity · United States1CompletedJul 17, 2026120
NCT07085468Body Weight · United States, Canada2TerminatedAug 14, 20251
NCT07073170Diabetes Mellitus, Type 2 · China1CompletedJan 27, 202636
NCT07030868Obesity · United States, Argentina2TerminatedJul 29, 20251
NCT06869018Diabetes Mellitus, Type 2 · Japan1CompletedMar 2, 202692
NCT06683508Obesity · United States2CompletedJan 7, 2026288
NCT06194500Healthy Male · United Kingdom1CompletedFeb 15, 202418
NCT06143956Obesity · United States, Argentina2RecruitingSep 20271,481
NCT05327595Diabetes Mellitus, Type 2 · Germany1CompletedApr 22, 202480
NCT04758234Healthy · United States1CompletedJan 10, 202254

How it is read

Names in the registry

  • “LY3549492”, 10 entries
  • “[14C]-LY3549492”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.